Immunicum AB CEO to present at BIO CEO & Investor Conference

GOTHENBURG, Sweden, February 3, 2017 – Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that Carlos de Sousa, MD, CEO of Immunicum, will present at the BIO CEO & Investor Conference which will be held February 13-14, 2017 at the Waldorf Astoria, New York, NY.

Presentation Information:

Date: Monday, February 13, 2017
Time: 5:00 PM EST
Presentation Room: Duke of Windsor

For more information, please contact
Carlos de Sousa, CEO, Immunicum
Ph: +46 (0) 31 41 50 52

About Immunicum AB (publ)
Immunicum AB (First North Premier: IMMU.ST) is a clinical stage company developing novel immuno-oncology therapies against a range of solid tumors. The Company’s lead compound, INTUVAX® is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. INTUVAX® was designed to combine the best of two worlds: a cost-effective cell-based (allogeneic) and off-the-shelf therapy that is capable of triggering a highly personalized and potentially long-lasting immune response against tumor cells throughout the body.

The Company’s Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31

Keep reading

Immunicum AB announces FDA clearance of its Investigational New Drug application for INTUVAX in metastatic renal cell carcinoma